---
title: "On the morning of the second day of the 2025 National Conference: Concentrated negotiations on tumor drugs, Astrazeneca, Roche, and others participate"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263650318.md"
description: "From the on-site negotiations of the national medical insurance catalog and the price negotiations for innovative drugs with commercial insurance in 2025, it was learned that the second day of the national negotiations in 2025 began around 8 a.m. The main varieties for negotiation today are anti-tumor drugs and chronic disease medications. Representatives from companies such as AstraZeneca, KELUN PHARMA, Roche, and Sanofi have entered the negotiation venue. A representative from a negotiating company expressed their personal opinion to reporters, stating, \"The ones with a higher possibility will likely be discussed first, while those with a slightly lower possibility will be arranged later.\""
datetime: "2025-10-31T03:30:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263650318.md)
  - [en](https://longbridge.com/en/news/263650318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263650318.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263650318.md) | [繁體中文](https://longbridge.com/zh-HK/news/263650318.md)


# On the morning of the second day of the 2025 National Conference: Concentrated negotiations on tumor drugs, Astrazeneca, Roche, and others participate

From the on-site negotiations of the national medical insurance catalog and the price negotiations for innovative drugs with commercial insurance in 2025, it was learned that the second day's process of the national negotiations began around 8 a.m. today, with anti-tumor drugs and chronic disease medications being the main varieties for negotiation. Representatives from companies such as AstraZeneca, KELUN PHARMA, Roche, and Sanofi have entered the negotiation venue. A representative from a negotiating company expressed to reporters their personal opinion that "those with a higher likelihood will be discussed first, while those with a slightly lower likelihood will be arranged later."

### 相关股票

- [Sanofi (SNY.US)](https://longbridge.com/zh-CN/quote/SNY.US.md)
- [AstraZeneca (AZN.US)](https://longbridge.com/zh-CN/quote/AZN.US.md)
- [Roche (RHHBY.US)](https://longbridge.com/zh-CN/quote/RHHBY.US.md)
- [KELUN PHARMA (002422.CN)](https://longbridge.com/zh-CN/quote/002422.CN.md)

## 相关资讯与研究

- [<![CDATA[FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer ]]>](https://longbridge.com/zh-CN/news/278576773.md)
- [AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals](https://longbridge.com/zh-CN/news/278917812.md)
- [AstraZeneca and Daiichi secure US fast-track status for cancer drug](https://longbridge.com/zh-CN/news/278343765.md)
- [AZ recruits Joshua Jackson, Gritty to cancer screening push](https://longbridge.com/zh-CN/news/278757381.md)
- [AstraZeneca Completes Key Japan Safety Study for Imfinzi/Imjudo in Liver Cancer](https://longbridge.com/zh-CN/news/278589537.md)